Limitations 1 : 1 : Results should be interpreted with caution because of the retrospective pre-post design without a control or comparator arm and the relatively short follow-up (6 months) Hypoglycemia may have been underreported, as only the clinically significant events were likely to have been captured (eg, no SMBG or CGM data) EMR database analysis as a potential for selection bias that cannot be controlled, as well as EMR data-capture challenges (eg, coding errors, no dosing data) Patients were mainly from the Northwest and Southern US states and therefore may not be representative of the US national landscape Sanofi-sponsored study *Follow-up period 6 months included GLP-1 RA + Toujeo (N=271)
Semaglutide drug monograph
Impact on providers like Priority Meds Priority Meds has not made public statements, as far as publicly available information shows, about how these regulatory changes affect their tirzepatide offerings
266 placebo) were categorized into 3 groups based on LVEF: 45% to 49% (n = 85), 50% to 59% (n = 215), and 60% (n = 229) (Table 1)
Always consult with your healthcare provider before starting any new supplement regimen to ensure it is safe and appropriate for your individual medical needs.
Trust your instinct and do not keep pushing methyl-folate